Adams Diversified Equity Fund Inc. Has $23,612,000 Stake in Pfizer, Inc. (PFE)

Adams Diversified Equity Fund Inc. continued to hold its position in Pfizer, Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 702,940 shares of the biopharmaceutical company’s stock at the close of the second quarter. Pfizer makes up approximately 1.3% of Adams Diversified Equity Fund Inc.’s portfolio, making the stock its 25th biggest position. Adams Diversified Equity Fund Inc.’s holdings in Pfizer were worth $23,612,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantitative Systematic Strategies LLC bought a new position in shares of Pfizer during the 2nd quarter worth $1,443,000. Huntington National Bank grew its position in shares of Pfizer by 1.7% during the 2nd quarter. Huntington National Bank now owns 1,868,974 shares of the biopharmaceutical company’s stock worth $62,779,000 after buying an additional 30,501 shares in the last quarter. Bridges Investment Counsel Inc. grew its position in shares of Pfizer by 96.9% during the 2nd quarter. Bridges Investment Counsel Inc. now owns 87,642 shares of the biopharmaceutical company’s stock worth $2,944,000 after buying an additional 43,140 shares in the last quarter. Private Bank & Trust Co. grew its position in shares of Pfizer by 0.8% during the 2nd quarter. Private Bank & Trust Co. now owns 64,124 shares of the biopharmaceutical company’s stock worth $2,154,000 after buying an additional 478 shares in the last quarter. Finally, Hermes Investment Management Ltd. grew its position in shares of Pfizer by 0.6% during the 2nd quarter. Hermes Investment Management Ltd. now owns 564,042 shares of the biopharmaceutical company’s stock worth $18,946,000 after buying an additional 3,473 shares in the last quarter. 69.09% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/09/10/adams-diversified-equity-fund-inc-has-23612000-stake-in-pfizer-inc-pfe.html.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the transaction, the insider now directly owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 426,291 shares of company stock valued at $14,475,911. Insiders own 0.06% of the company’s stock.

A number of equities analysts have recently issued reports on PFE shares. Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. UBS AG reissued a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets reissued a “buy” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday. Finally, Jefferies Group LLC reissued a “hold” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Friday, July 14th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $37.61.

Shares of Pfizer, Inc. (NYSE:PFE) traded up 0.32% during midday trading on Friday, reaching $34.10. The company’s stock had a trading volume of 15,442,446 shares. The stock’s 50-day moving average price is $33.36 and its 200-day moving average price is $33.49. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $34.75. The company has a market cap of $202.80 billion, a P/E ratio of 24.95 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 EPS. On average, analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were given a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.75%. Pfizer’s dividend payout ratio is currently 94.12%.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply